ERBB2 and neoplasm: Well-characterized stem cell markers CD44 and CD24 have been linked to younger age at diagnosis, higher odds of unfavorable tumor characteristics, including triple-negative receptor status (estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2)), and distant metastasis [24–26].